

S3 Table. Baseline characteristics of patients treated at Memorial Sloan Kettering Cancer Center (n=240)

Variable	Total (n=240)	<i>TP53</i> MT (n=141)	<i>TP53</i> WT (n=99)	p-value
Age ^{a)} (yr)				0.319
< 65	111 (46.3)	69 (48.9)	42 (42.4)	
≥ 65	129 (53.8)	72 (51.1)	57 (57.6)	
Sex				0.335
Male	118 (48.2)	73 (51.8)	45 (45.5)	
Female	122 (50.8)	68 (48.2)	54 (54.5)	
Smoking status				0.029
Never smoker	47 (19.6)	21 (14.9)	26 (26.3)	
Former smoker	193 (80.4)	120 (85.1)	73 (73.7)	
Histologic type				0.052
Adenocarcinoma	186 (77.5)	102 (72.3)	84 (84.8)	
Squamous cell carcinoma	34 (14.2)	26 (18.4)	8 (8.1)	
Others ^{b)}	20 (8.3)	13 (9.2)	7 (7.1)	
Type of ICI				0.700
Monotherapy	206 (85.8)	120 (85.1)	86 (86.9)	
Combination ^{c)}	34 (14.2)	21 (14.9)	13 (13.1)	
Prior treatment line				0.196
1	51 (21.3)	34 (24.1)	17 (17.2)	
≥ 2	189 (78.8)	107 (75.9)	82 (82.8)	
PD-L1				0.008
<1%	42 (17.5)	14 (9.9)	28 (28.3)	
1-49%	23 (9.6)	14 (9.9)	9 (9.1)	
≥ 50%	21 (8.8)	15 (10.6)	6 (6.1)	
Unknown	154 (64.2)	98 (69.5)	56 (56.6)	
TMB cutoff of NGS				0.292
< 10 mut/Mb	158 (65.8)	71 (50.4)	87 (87.9)	
≥ 10 mut/Mb	82 (34.2)	70 (49.6)	12 (12.1)	

Values are presented as number (%). ICI, immune checkpoint inhibitor; PD-L1, programmed death-ligand 1; MT, mutated; TMB, tumor mutation burden; WT, wild-type. ^{a)}At ICI initiation, ^{b)}This includes large-cell neuroendocrine type (n=7), and non-small cell lung cancer (n=13), ^{c)}ICI treatment combined with cytotoxic T-cell lymphocyte-4 inhibitor.